CN106478784A - 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 - Google Patents
用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 Download PDFInfo
- Publication number
- CN106478784A CN106478784A CN201610854932.1A CN201610854932A CN106478784A CN 106478784 A CN106478784 A CN 106478784A CN 201610854932 A CN201610854932 A CN 201610854932A CN 106478784 A CN106478784 A CN 106478784A
- Authority
- CN
- China
- Prior art keywords
- antigen
- hpv
- antibody
- seq
- papilloma virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 65
- 108091007433 antigens Proteins 0.000 title claims abstract description 65
- 102000036639 antigens Human genes 0.000 title claims abstract description 65
- 238000001514 detection method Methods 0.000 title claims abstract description 57
- 241001631646 Papillomaviridae Species 0.000 title claims abstract description 34
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 45
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 19
- 230000036039 immunity Effects 0.000 claims abstract description 16
- 210000003296 saliva Anatomy 0.000 claims abstract description 12
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract description 4
- 238000002965 ELISA Methods 0.000 claims description 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 25
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002159 nanocrystal Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 27
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 19
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 19
- 201000010881 cervical cancer Diseases 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 13
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000009792 diffusion process Methods 0.000 abstract description 4
- 108700020796 Oncogene Proteins 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 102000043276 Oncogene Human genes 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 239000007788 liquid Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 206010059313 Anogenital warts Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010827 pathological analysis Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 241000722343 Human papillomavirus types Species 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 208000025661 ovarian cyst Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 241001282153 Scopelogadus mizolepis Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种人***瘤病毒HPV致癌基因蛋白作为抗原，用于检测抗人***瘤病毒HPV的抗体，其序列如SEQ ID NO:5所示。还提供了包括上述抗原的免疫检测试剂盒。以及上述抗原和试剂盒的应用。本发明的用于检测抗HPV抗体的抗原可以高灵敏度、高特异性和高稳定性地检测血液或唾液中的HPV抗体，从而可以为医生准确诊断病人有HPV病毒致癌基因转化的宫颈上皮内瘤变和子***带来依据，进而及时采取治疗，以防止癌症发生，或癌症扩散，及时减轻病人痛苦，由其制成的免疫检测试剂盒可以快速简单准确地检测血液或唾液中的HPV抗体，适于大规模推广应用。
Description
本申请是申请日为2013年2月22日、申请号为201310056516.3、发明名称为“用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒”的发明申请的分案申请。
技术领域
本发明涉及抗体检测技术领域，特别涉及抗人***瘤病毒(HumanPapillomavirus，HPV)抗体检测技术领域，具体是指一种用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒，尤其可用于国内流行的高危险型人***瘤病毒(HPV)亚型HPV16和HPV18。
背景技术
子***是第二位常见女性恶性肿瘤，人乳状瘤病毒(HPV)是其发生的必要条件。尽管人群HPV感染很普遍，如：***高发区妇女35岁以后感染率仍高达20.8％。但超过80％的HPV DNA阳性妇女不会进展为癌症或癌前病变。因此HPV DNA检测缺陷是无法分辨一过性感染和可引起宫颈病变的感染，导致较高假阳性率。大量研究显示，HPV致癌基因表达产物(癌蛋白oncoprotein)有很高的致癌活性，因此这些生物标志物有可以作为比HPV DNA更为准确有特异性的***预测指标。高危HPV E2、E6、E7癌蛋白(oncoprotein)的表达水平和***前病变不同阶段直接相关。利用这一特性可以构建全新的***分子筛查指标。
对HPV致癌机理的研究表明，高危型HPV的早期表达蛋白E6，E7蛋白在***的发生中起着重要作用。在宫颈高度病变和癌症患者的宫颈上皮细胞中HPV E6及E7蛋白一般呈过度表达，持续表达和过量表达的E6，E7致癌蛋白可与宿主细胞调控蛋白(如，P53和Rb蛋白等)相互作用，使肿瘤抑制因子失活，导致细胞永生化和恶性转化。
除了HPV DNA检测和HPV致癌蛋白检测，血液(体液)中HPV抗体也证明对HPV感染及***发病史有很大的相关性。HPV L1血液抗体可用标准ELISA方法检测,提供HPV感染信息。随着HPV感染时间的延长，HPV诱导产生了抗HPV抗体，故可检测到血清中抗HPV抗体。Wikstrom等检测了47例男性现症***患者和32例曾有***病史患者的男性对HPV6型和HPV11型衣壳蛋白的血清IgG抗体，并与205例无生殖器***病史的男性比较，结果，血清中抗HPV6型的IgG抗体在曾有***病史的男性中为35％，在现症***中为27％，而在对照组为10％。这表明抗HPV6 IgG抗体的出现发生在*** 病期的晚些时候，同时IgG阳性也反映曾感染过这种病毒。
Stone等报道了利用此方法对于美国普通人群7218例HPV-16的感染率研究，结果表明女性阳性率17.9％，男性阳性率7.9％(Stone，K.M.,et al.,Seroprevalence ofHuman Papillomavirus Type 16Infection in the United States.2002.The Journalof Infectious Diseases 2002；186:1396–402)。HPV L1抗体ELISA方法在配合HPV疫苗(Merck公司Gardasil预防性疫苗)的研发及临床试验过程中曾被广泛采用。Luevano等用蛋白芯片例***病人的血清样品进行了高通量检测分析(Luevano,M.,et al.,High-Throughput Profiling of the Humoral Immune Responses Against Thirteen HumanPapillomavirus Types by Proteome Microarrays.2010.Virology.2010；405(1):31–40)，分析13个HPV型的总共54604种蛋白的抗体profiling，结果表明了血液中致癌蛋白的抗体与***、高度病变、低度病变、及无症状普通人有较强的相关性(Luevano,M.,etal.,High-Throughput Profiling of the Humoral Immune Responses AgainstThirteen Human Papillomavirus Types by ProteomeMicroarrays.2010.Virology.2010；405(1):31–40)。
因此，为了实现HPV抗体检测的高灵敏度、高特异性和高稳定性，需要提供新的用于检测抗人***瘤病毒抗体的抗原。
发明内容
为了解决上述存在的问题，本发明的目的是提供一种用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒，该用于检测抗人***瘤病毒抗体的抗原可以高灵敏度、高特异性和高稳定性地检测血液或唾液中的HPV抗体，从而可以为医生准确诊断病人宫颈上皮内瘤变和子***带来依据，进而及时采取治疗，以防止癌症发生，或癌症扩散，及时减轻病人痛苦，由其制成的免疫检测试剂盒可以快速简单准确地检测血液或唾液中的HPV抗体，适于大规模推广应用。
为了实现上述目的，在本发明的第一方面，提供了一种用于检测抗人***瘤病毒抗体的抗原，其特点是，所述的用于检测抗人***瘤病毒抗体的抗原选自如SEQ ID NO:1所示的氨基酸序列、如SEQ ID NO:2所示的氨基酸序列、如SEQ ID NO:3所示的氨基酸序列、如SEQ ID NO:4所示的氨基酸序列、如SEQ ID NO:5所示的氨基酸序列、与SEQ ID NO:1所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:2所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:3所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:4所示的氨基酸序列具有80％同源性的氨基酸序列以及与SEQ ID NO:5所示的氨基酸序列具有80％同源性的氨基酸序列中的一种或几种。
较佳地，所述的用于检测抗人***瘤病毒抗体的抗原的第m+2位、第m+3位、第m+5位、第m+6位以及第m+8-m+12位氨基酸依次是Asp、Ser、Glu、Glu、Asp、Glu、Ile、Asp和Gly，其中m≥0。
较佳地，所述的用于检测抗人***瘤病毒抗体的抗原采用化学合成或生物工程方法获得。例：重组蛋白，融合蛋白。
在本发明的第二方面，提供了一种免疫检测试剂盒，其特点是，包括上述的用于检测抗人***瘤病毒抗体的抗原。
较佳地，所述免疫检测试剂盒还包括载体，所述的用于检测抗人***瘤病毒抗体的抗原包被在所述载体上。
较佳地，所述免疫检测试剂盒还包括标记的抗人***瘤病毒抗体的二抗。二抗用来检测人血清中的抗体IgG，IgM，或IgA.所用标记物可以是辣根过氧化物酶，碱性磷酸酶，荧光分子FITC(或其它荧光标记)，化学发光检测。检测方法可以是显色法，荧光方法，化学发光，电化学发光法进行定性、定量分析。
更佳地，所述的标记的抗人***瘤病毒抗体的二抗是辣根过氧化物酶标记的抗人***瘤病毒抗体的二抗。
在本发明的第三方面，提供了上述的用于检测抗人***瘤病毒抗体的抗原或上述的免疫检测试剂盒在检测人体液中抗人***瘤病毒抗体中的应用。
较佳地，所述体液是血液或唾液。
本发明的有益效果在于：本发明的用于检测抗人***瘤病毒抗体的抗原选自如SEQ ID NO:1所示的氨基酸序列、如SEQ ID NO:2所示的氨基酸序列、如SEQ ID NO:3所示的氨基酸序列、如SEQ ID NO:4所示的氨基酸序列、如SEQ ID NO:5所示的氨基酸序列、与SEQID NO:1所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:2所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:3所示的氨基酸序列具有80％同源性的氨基酸序列、与SEQ ID NO:4所示的氨基酸序列具有80％同源性的氨基酸序列以及与SEQ IDNO:5所示的氨基酸序列具有80％同源性的氨基酸序列中的一种或几种，病人在被病毒感染后，可在血清和口腔唾液中高特异性、高灵敏度、高特异性地地检测出现的特异性的抗体IgM，IgA或IgG分子，从而可以为医生准确诊断病人宫颈上皮内瘤变和子***带来依据，进而及时采取治疗，以防止癌症发生，或癌症扩散，及时减轻病人痛苦，以此制成的免疫检测试剂盒，可以快速简单准确地检测血液或唾液中的HPV抗体，适于大规模推广应用。
具体实施方式
为了能够更清楚地理解本发明的技术内容，特列举以下具体实施例详细说明。然而，具体实施例仅仅是用于举例说明，而不是对本发明的限制。
一、材料与方法
1、试剂和药品
辣根过氧化物酶标记羊抗人(Goat Anti-Human IgG,FC)，购自Priece Product#31413。
氯化钠、氯化钾、磷酸氢二钠、磷酸二氢钾购自国药集团化学试剂有限公司。Tween-20购自AMRESCO。胎牛血清购自北京元亨金马生物技术开发有限公司。
2、仪器和耗材
电子天平(梅特勒-托利多仪器上海有限公司)；85-1恒温磁力搅拌器(江苏金坛市杰瑞尔电器有限公司)；MULTISKAN MK3酶标仪(Thermo公司)；超纯水制备装置(美国MILLPORE公司)；GZX-9240MBE数显鼓风干燥箱(上海博迅实业有限公司医疗设备厂)；WellWASK4MK2洗板机(购自Thermo公司)；酶标板(COSTAR公司)；单道、多道移液器(德国eppendorf公司)。
3、主要溶液***
·包被缓冲液(PBS磷酸盐溶液)：磷酸二氢钾0.2g，12水磷酸氢二钠2.9g，氯化钠8.0g，氯化钾0.2g，加蒸馏水至1L，4度保存。
·洗涤缓冲液(PBS-Tween 20，0.1％)：Tween-20 1mL，加入到1L稀释缓冲液(PBS)中，搅拌混匀，调pH值到7.0～7.2之间。
·封闭液：5％milk-PBS-Tween
·血清稀释液：10％FBS-PBS-Tween
·TMB显示液：Amresc，CAT NO.64285730，用前TMB底色显色A液和B液等体积混合。
o底物显色A液：乙酸钠13.6g，柠檬酸1.6g，双氧水(30％)0.3ml，蒸馏水加至500ml。
o底物显色B液：乙二胺四乙酸二钠0.2g柠檬酸0.95g甘油50ml四甲基联苯胺0.2g蒸馏水加至500ml。
·终止液(2mol/L H2SO4)：双蒸水178.3mL，滴加浓硫酸(98％)21.7mL。
4、间接ELISA方法的建立
1)用PBS稀释HPV多肽抗原HPV16-1/HPV16-2/HPV16-3/HPV18-1/HPV18-2浓度为4ug/ml，包被costar板条100ul/孔，4℃过夜。
2)PBS洗涤一次，拍干。
3)加入5％奶粉-PBS封闭，250ul/孔，37度3小时。
4)PBST洗涤一次，拍干。
5)10％FBS-PBST稀释血清1：50稀释，振荡器混匀。
6)加入稀释好的血清，空白对照，阴性对照以及阳性对照，50ul/孔，37度孵育1小时。
7)0.1％tween-PBS洗涤5次，拍干。
8)加入辣根过氧化物酶标记羊抗人，用10％FBS-PBST稀释(1：40000)，100ul/孔，37度孵育30分钟。
9)0.1％tween-PBS洗涤5次，拍干。
10)TMB显色:TMB A液和B液等体积混合，100ul/孔，37度20min。
11)2M H2SO4，50ul/孔终止，用酶标仪450nm读数。
5、试剂盒组成：
本试剂盒由以下几个部分组成：
1.包被本发明的用于检测抗人***瘤病毒抗体的抗原的costar酶标板一块
2.辣根过氧化物酶标记羊抗人一管(10ul)
3.10*PBST一瓶(10ml)
4.TMB显色液A液一瓶(6ml)，B液一瓶(6ml)
5.终止液一瓶(6ml)
6、包被抗原
多肽抗原如下
| HPV16-1 | KCDSTLRLCVQSTHVDIRTLE | SEQ ID NO：1 |
| HPV16-2 | PTLHEYMLDLQPETTDLYCYEQLNDSSEEE | SEQ ID NO：2 |
| HPV16-3 | LNDSSEEEDEIDGPAGQAEPDRAH | SEQ ID NO：3 |
| HPV18-1 | IDGVNHQHLPARRAEPQR | SEQ ID NO：4 |
| HPV18-2 | SDSEEENDEIDGVNHQHLPARRAEPQRH | SEQ ID NO：5 |
二、检测结果
试剂盒选择5条多肽(SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4，SEQID NO：5)作为包被选择，通过ELISA方法检测血清。
1、用包被抗原并封闭过的酶标板通过ELISA方法检测健康人血清，检测的原始数据结果如下；
表一：HPV血液ELISA检测正常人血清结果表
2、选择2条多肽(SEQ ID NO：3，SEQ ID NO：5)作为包被选择并封闭过的酶标板通过ELISA方法检测正常人血清，检测的原始数据结果如下；
表二：HPV血液ELISA检测正常人血清结果表
3、选择5条多肽(SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4，SEQ IDNO：5)作为包被选择包被并封闭过的酶标板通过ELISA方法检测病人血清，病人的病理诊断结果如表三中所示，其中部分病人经过HC2病理检验，结果如下：
表三：HPV血液ELISA检测病人血清结果表
4、选择3条多肽(SEQ ID NO：1，SEQ ID NO：3，SEQ ID NO：5)作为包被选择包被并封闭过的酶标板通过ELISA方法检测病人血清，病人的病理诊断结果如表四中所示，其中部分病人经过HC2病理检验，结果如下：
表四：HPV血液ELISA检测病人血清结果表
三、数据分析
1、根据正常人检测值，计算出平均值，标准方差，CUTOFF值。分别将表一中的44例正常人血清在HPVE7多肽上的反应OD值取平均数，并计算标准方差SD，本试剂盒在确定CUTOFF值时选择正常人平均值加上两倍的标准方差作为HPV阴阳性的判断标准，结果如下：
Cutoff计算公式为：cutoff＝平均值OD+2*SD标准方差
1.1根据表一结果，HPVE7(SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ IDNO：4，SEQ ID NO：5)5条多肽检测正常人血清结果统计分析得出，结果如下表：
表五：HPV E7的5条多肽血清ELISA检测数据表
| SEQ ID NO：1 | SEQ ID NO：2 | SEQ ID NO：3 | SEQ ID NO：4 | SEQ ID NO：5 | |
| 平均值 | 0.292 | 0.279 | 0.382 | 0.301 | 0.383 |
| 标准方差 | 0.098 | 0.100 | 0.111 | 0.076 | 0.111 |
| cutoff | 0.487 | 0.480 | 0.604 | 0.452 | 0.605 |
1.2根据表二结果，HPVE7(SEQ ID NO：3和SEQ ID NO：5)2条多肽检测正常人血清结果统计分析得出，结果如下表：
表六：HPV E7的2条多肽血清ELISA检测数据表
1.3根据表五和表六的结果，对比分析得出SEQ ID NO：3和SEQ ID NO：5这2条多肽在不同实验时得出的cutoff值一致。
2、通过cutoff值，判断检测的病人血清HPV的阴性、阳性，超过这个cutoff值的即认为是阳性，且只要一个多肽检测为阳性，即认为有HPV感染，同时与HC2诊断结果对比。
2.1在检测的病人血清中291例血清有HC2诊断结果，有病理诊断阳性的病例84例.在病理阳性病人组(临床诊断”金标准”),血清抗体检测结果与HC2分子检测结果相对比(见表7)，将其与本试剂盒检测HPV结果进行对比如下表：(本检测结果中统计为阳性的包括：(i)两个抗原检测结果有任何一个是阳性结果，(ii)两个抗原检测结果都是阳性结果)
表七：根据表三的结果，对于病人的血清ELISA诊断结果与HC2诊断结果对比表(“+”表示检测结果阳性；“-”表示检测结果阴性)
表八：根据表四的结果，对于病人的血清ELISA诊断结果与HC2诊断结果对比表(“+”表示检测结果阳性；“-”表示检测结果阴性)
将表七结果的HC2结果和血液ELISA检查结果进行人数统计分析，结果如下表：
表九：HC2结果与血液ELISA检测准确率人数及比例对比表
其他妇科疾病主要为***，***，子宫肌瘤等妇科疾病。
将表八结果的HC2结果和血液ELISA检查结果进行人数统计分析，结果如下表：
表十：HC2结果与血液ELISA检测准确率人数及比例对比表
其他妇科疾病主要为***，***，子宫肌瘤等妇科疾病。
2.2检测病人血清中有10例血清为没有HC2检测报告，但病理报告为CIN和***，本试剂盒检测HPV结果，病人数及血液检测阳性率对比结果如表。
表十一：对于没有HC2诊断结果，但有病理结论的病人与HPV血液ELISA检测结果总结(“+”表示检测结果阳性；“-”表示检测结果阴性)
表十二：无HC2结果的CIN，***及宫颈病变的病人血液ELISA检测的人数表
| 病理 | 人数(10) | SEQ ID NO：1阳性 | SEQ ID NO：3阳性 | SEQ ID NO：5阳性 |
| CINⅠ | 2 | 2 | 1 | 1 |
| CINⅡ，Ⅲ | 7 | 4 | 5 | 5 |
| *** | 1 | 0 | 1 | 1 |
2.3将所有CINⅠⅡⅢ和***的病人血液ELISA检测结果统计人数及阳性比例结果如表十三。
表十三：所有CIN，***及宫颈病变的病人血液ELISA检测的人数及准确率比例表
本发明的上述多肽是经过发明人的选择并在病人样品及正常人样品中进行了检测验证，而直接采用GST-HPV16-E7和GST-HPV118E7全长融合蛋白(分别为SEQ ID NO：6、SEQIDNO：7所示序列)检测血清，效果不佳，请参见下列实验数据。或
四、实验材料和ELISA方法同前面第一点，只是采用多肽(SEQ ID NO：3，SEQ IDNO：5)检测的同时，还采用GST-HPV16-E7和GST-HPV118E7全长融合蛋白作为检测抗原，在用PBS稀释GST-HPV16-E7、GST-HPV18-E7全长融合蛋白时，浓度均为2ug/ml，检测结果如下：
1.根据上面实验步骤，检测部分病人血清和普通人血清，检测结果和病人病理报告如下表所示：
五.实验分析
1.将使用全长蛋白的检测结果与之前采用HPV多肽SEQ ID:3和SEQ ID:5两种多肽联合检测结果对比，对比如下表：
总结：总结：HPV16-E7，HPV18-E7全长融合蛋白在检测CIN，***病人时有一定的阳性病人漏检，灵敏性比多肽检测差。在检测普通妇科炎症病人和普通人群时有一定的假阳性率，敏感性比多肽检测略差。所以，HPV16-E7和HPV18-E7全长蛋白对于检测CIN，***等不是很适合。
本发明的血液酶标免疫分析法(ELISA)以免疫生化原理为基础，提供高灵敏度，高特异性和高稳定性的抗原-抗体检测方法。病人在被病毒感染后，可在血清和口腔唾液中出现特异性的抗体IgM,IgA或IgG分子。用酶标免疫分析法ELISA检测病人血清或唾液中特异性抗HPV的抗体分子。本发明通过对HPV病毒高危型HPV16，HPV18基因序列的分析，用生物信息学分析对抗原性的理论预测，并用实验方法筛选、证明临床应用的意义。通过制备多个高纯度的抗原多肽，并以国内人群健康者血清和感染者血清对制备抗原进行反复筛选、验证，获得了有高灵敏度，高特异性和高稳定性的目的抗原HPV16-1、HPV16-2、HPV16-3、HPV18-1、HPV18-2。并证明用这些多肽抗原结合到某种固相载体表面，能保持其免疫反应活性。在测定时，使受检标本与固相载体表面的抗原起反应。用洗涤的方法使固相载体上形成的抗原、抗体复合物与其他物质分开，最后是结合在固定载体上的酶量与标本中受检物质的量成一定的比例。加入酶反应的底物后，然后通过显色来检测，故可根据颜色反应的深浅作定性或定量分析。本发明的血液ELISA检测试剂盒与DNA检测(HC2,CareHPV)相比,取样均匀，非侵略性，操作更为快速，简单；费用便宜，容易推广，更适合中国市场；可避免PCR方法带来的假阳性和假阴性，大大提高了检测结果的精确度和准确度；与传统的巴氏涂片、醋酸染色VIA，***镜检查相比，更为准确、容易、快速。ELISA检测方法经各种参数和实验程上的优化，可作为大规模筛选的工具用于***的早期筛查。
综上，本发明的用于检测抗人***瘤病毒抗体的抗原可以高灵敏度、高特异性和高稳定 性地检测血液或唾液中的HPV抗体，从而可以为医生准确诊断病人宫颈上皮内瘤变和子***带来依据，进而及时采取治疗，以防止癌症发生，或癌症扩散，及时减轻病人痛苦，由其制成的免疫检测试剂盒可以快速简单准确地检测血液或唾液中的HPV抗体，适于大规模推广应用。
在此说明书中，本发明已参照其特定的实施例作了描述。但是，很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此，说明书应被认为是说明性的而非限制性的。
Claims (10)
1.一种用于检测抗人***瘤病毒抗体的抗原，其特征在于，所述用于检测抗人***瘤病毒抗体的抗原的氨基酸序列如SEQ ID NO.5所示。
2.一种用于检测抗人***瘤病毒抗体的抗原组合，其特征在于，所述抗原组合包括如SEQ ID NO.5所示的氨基酸序列的抗原；
优选地，所述抗原组合还包括选自下组一种或多种抗原：如SEQ ID NO:1所示的氨基酸序列的抗原、如SEQ ID NO:2所示的氨基酸序列的抗原、如SEQ ID NO:3所示的氨基酸序列的抗原、如SEQ ID NO:4所示的氨基酸序列的抗原；更优选地，所述抗原组合还包括SEQ IDNO:3所示的氨基酸序列的抗原。
3.一种组合物，其特征在于，所述的组合物含有权利要求1所述的抗原、或权利要求2所述的抗原组合，以及药学上可接受的载体和/或辅料；
优选地，所述组合物为试剂、疫苗或药物组合物。
4.一种免疫检测试剂盒，其特征在于，包括根据权利要求1所述的用于检测抗人***瘤病毒抗体的抗原或权利要求2所述的用于检测抗人***瘤病毒抗体的抗原组合。
5.如权利要求4所述的免疫检测试剂盒，其特征在于，所述免疫检测试剂盒还包括载体，所述抗原包被在所述载体上。
6.如权利要求4所述的免疫检测试剂盒，其特征在于，所述免疫检测试剂盒还包括标记物标记的抗人***瘤病毒抗体的二抗；
优选地，所述标记物选自下组：辣根过氧化物酶、碱性磷酸酶、萤光标记、化学发光标记。
7.根据权利要求1所述的用于检测抗人***瘤病毒抗体的抗原、根据权利要求2所述的用于检测抗人***瘤病毒抗体的抗原组合在制备试剂中的用途，其中所述试剂用于检测人***瘤病毒抗体。
8.如权利要求7所述的用途，其特征在于，所述试剂还用于诊断宫颈上皮内瘤变或子***。
9.根据权利要求1所述的用于检测抗人***瘤病毒抗体的抗原、根据权利要求2所述的用于检测抗人***瘤病毒抗体的抗原组合或根据权利要求4所述的免疫检测试剂盒在检测人体液中抗人***瘤病毒抗体中的应用；
优选地，所述体液是血液或唾液。
10.一种检测抗人***瘤病毒抗体的方法，其特征在于，所述方法包括步骤：
将权利要求1所述的抗原或权利要求2所述的抗原组合与待测样本接触，检测是否形成抗原抗体复合物，其中，所述抗原抗体复合物中的抗体为抗人***瘤病毒抗体，所述抗原抗体复合物中的抗原为权利要求1所述的抗原或权利要求2所述的抗原组合中的抗原；
优选地，所述方法为ELISA方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610854932.1A CN106478784B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056516.3A CN104004067B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
| CN201610854932.1A CN106478784B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310056516.3A Division CN104004067B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106478784A true CN106478784A (zh) | 2017-03-08 |
| CN106478784B CN106478784B (zh) | 2019-10-25 |
Family
ID=51364995
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610854355.6A Active CN106632617B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
| CN201310056516.3A Active CN104004067B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
| CN201610854932.1A Active CN106478784B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610854355.6A Active CN106632617B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
| CN201310056516.3A Active CN104004067B (zh) | 2013-02-22 | 2013-02-22 | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 |
Country Status (2)
| Country | Link |
|---|---|
| CN (3) | CN106632617B (zh) |
| WO (1) | WO2014127741A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107868127A (zh) * | 2016-09-28 | 2018-04-03 | 艾托金生物医药（苏州）有限公司 | 一种用于检测病理组织切片中癌蛋白表达的单克隆抗体 |
| CN110596384B (zh) * | 2019-10-12 | 2022-08-12 | 南京黎明生物制品有限公司 | 基于Cas蛋白及gRNA复合物制备的人***瘤病毒6型和11型免疫检测试剂盒 |
| CN116162155B (zh) * | 2022-11-15 | 2023-09-29 | 北京义翘神州科技股份有限公司 | 抗hpv6 l1蛋白抗体及应用该抗体的检测方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018294A1 (en) * | 1990-05-11 | 1991-11-28 | Medscand Ab | Synthetic peptides of human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunossay for diagnostic purposes |
| CN1775802A (zh) * | 2004-11-17 | 2006-05-24 | 宋硕 | 人类***瘤病毒免疫原性多肽、其制备方法及应用 |
| CN103254307A (zh) * | 2012-02-16 | 2013-08-21 | 艾托金生物医药（苏州）有限公司 | Hpv18e7单克隆抗体、相关杂交瘤细胞株和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE234860T1 (de) * | 1991-07-13 | 2003-04-15 | Dade Behring Marburg Gmbh | Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| WO2001077142A1 (en) * | 2000-04-05 | 2001-10-18 | Impact Diagnostics, Inc. | Immunological methodology for discerning human papillomavirus |
| US7314630B2 (en) * | 2005-01-07 | 2008-01-01 | Yao-Xiong Hu | Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified |
-
2013
- 2013-02-22 CN CN201610854355.6A patent/CN106632617B/zh active Active
- 2013-02-22 CN CN201310056516.3A patent/CN104004067B/zh active Active
- 2013-02-22 CN CN201610854932.1A patent/CN106478784B/zh active Active
-
2014
- 2014-02-21 WO PCT/CN2014/072407 patent/WO2014127741A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018294A1 (en) * | 1990-05-11 | 1991-11-28 | Medscand Ab | Synthetic peptides of human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunossay for diagnostic purposes |
| CN1775802A (zh) * | 2004-11-17 | 2006-05-24 | 宋硕 | 人类***瘤病毒免疫原性多肽、其制备方法及应用 |
| CN103254307A (zh) * | 2012-02-16 | 2013-08-21 | 艾托金生物医药（苏州）有限公司 | Hpv18e7单克隆抗体、相关杂交瘤细胞株和应用 |
Non-Patent Citations (1)
| Title |
|---|
| CONRAD BLEUL,ET AL: "Human Papillomavirus Type 18 E6 and E7 Antibodies in Human Sera: Increased Anti-E7 Prevalence in Cervical Cancer Patients", 《JOURNAL OF CLINICAL MICROBIOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104004067B (zh) | 2017-09-01 |
| CN106478784B (zh) | 2019-10-25 |
| WO2014127741A1 (zh) | 2014-08-28 |
| CN106632617B (zh) | 2020-07-03 |
| CN104004067A (zh) | 2014-08-27 |
| CN106632617A (zh) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7972776B2 (en) | Protein chips for HPV detection | |
| US7316908B2 (en) | Peptides from the E2 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers | |
| US7732166B2 (en) | Detection method for human pappilomavirus (HPV) and its application in cervical cancer | |
| JP2012529009A (ja) | ウイルス抗原への直接蛍光イムノアッセイ | |
| Zhang et al. | A novel enhanced substrate for label-free detection of SARS-CoV-2 based on surface-enhanced Raman scattering | |
| CN110568178B (zh) | 一种寨卡病毒ns1抗原及其在制备荧光免疫层析试剂中的应用 | |
| Xu et al. | EuNPs-mAb fluorescent probe based immunochromatographic strip for rapid and sensitive detection of porcine epidemic diarrhea virus | |
| CN103342738B (zh) | 人***瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽 | |
| CN106885903A (zh) | 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用 | |
| CN106478784B (zh) | 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒 | |
| CN111044728B (zh) | 用于快速检测腺病毒的IgM抗体胶体金试纸条及其制备方法 | |
| WO2023040026A1 (zh) | 免疫层析检测试剂条和包含其的试剂盒及二者的应用 | |
| US6743593B2 (en) | Immunological methodology for discerning human papillomavirus | |
| Wang et al. | Recent advances in immunoassay technologies for the detection of human coronavirus infections | |
| Pagliusi et al. | International standard reagents for HPV detection | |
| CN110964089B (zh) | 一种肺炎支原体抗原 | |
| TWI497075B (zh) | 早期及晚期人類乳突病毒感染之偵測 | |
| CN203249922U (zh) | 用于检测抗人***瘤病毒抗体的免疫检测试剂盒 | |
| CN108761091A (zh) | 双抗夹心法快速检测hpv抗体的试纸条、试纸卡及其制备方法 | |
| CN103940993A (zh) | 用于检测抗人***瘤病毒抗体的抗原及试剂盒和应用 | |
| CN209280731U (zh) | 一种快速检测麻疹病毒感染试剂盒 | |
| CN112444626B (zh) | 一种非洲猪瘟病毒抗体elisa检测试剂盒及其制备方法 | |
| Budama‐Kilinc et al. | Influenza diagnosis with a specific emphasis on the M2e antigen as a diagnostic tool | |
| CN115850424A (zh) | 一种up蛋白片段及其在人源包虫病中的应用 | |
| CN118130785A (zh) | 一种猴痘病毒免疫标记物及其在磁/光三模式免疫层析检测猴痘病毒中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Antigen and related immunoassay kit for detecting anti human papillomavirus antibody Effective date of registration: 20211020 Granted publication date: 20191025 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20191025 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Antigen and related immune detection kit for detecting antibodies against human papillomavirus Granted publication date: 20191025 Pledgee: Suzhou Beiming Intelligent Manufacturing Co.,Ltd. Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2024990000122 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |